Original Source(s)
Related Content
FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI
The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.
June 15, 2026
-
3 min
When Should Breast Cancer Risk Scores Trigger MRI?
A JAMA Internal Medicine Viewpoint urges clinicians and health systems to verify risk-model inputs before acting on automated breast cancer screening recommendations.
by Kerri Miller
June 23, 2026
-
3 min
Symptom Scores May Signal Neuropathy Risk
Early recovery symptom patterns may help clinicians identify which oropharyngeal cancer survivors warrant closer neurologic surveillance.
May 6, 2026
-
4 min